MRNA Moderna Inc

Price (delayed)

$129.65

Market cap

$51.3B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.61

Enterprise value

$50B

Sector: Healthcare
Industry: Biotechnology

Moderna is an American, Cambridge, Massachusetts-based biotechnology company focused on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA . The Moderna technology platform is to insert ...

Highlights

MRNA's gross profit has soared by 133% from the previous quarter
MRNA's revenue has soared by 133% since the previous quarter
The equity has soared by 120% YoY but it is down by 6% QoQ
The company's EPS rose by 27% YoY but it fell by 16% QoQ
The quick ratio has plunged by 86% from the previous quarter and by 67% YoY
The debt has grown by 24% since the previous quarter

Key stats

What are the main financial stats of MRNA
Market
Shares outstanding
395.71M
Market cap
$51.3B
Enterprise value
$50B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
18.54
Price to sales (P/S)
207.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
202.69
Earnings
Revenue
$246.71M
EBIT
-$596.79M
EBITDA
-$564.3M
Free cash flow
$616.1M
Per share
EPS
-$1.61
Free cash flow per share
$1.56
Book value per share
$6.99
Revenue per share
$0.63
TBVPS
$11.78
Balance sheet
Total assets
$4.65B
Total liabilities
$1.89B
Debt
$207.56M
Equity
$2.76B
Working capital
$2.1B
Liquidity
Debt to equity
0.08
Current ratio
2.43
Quick ratio
2.35
Net debt/EBITDA
2.3
Margins
EBITDA margin
-228.7%
Gross margin
100%
Net margin
-242.3%
Operating margin
-250.2%
Efficiency
Return on assets
-20.3%
Return on equity
-28.1%
Return on invested capital
-36%
Return on capital employed
-18.8%
Return on sales
-241.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MRNA stock price

How has the Moderna stock price performed over time
Intraday
-0.05%
1 week
14.99%
1 month
-11.93%
1 year
540.56%
YTD
24.1%
QTD
24.1%

Financial performance

How have Moderna's revenue and profit performed over time
Revenue
$246.71M
Gross profit
$246.71M
Operating income
-$617.2M
Net income
-$597.7M
Gross margin
100%
Net margin
-242.3%
MRNA's gross profit has soared by 133% from the previous quarter
MRNA's revenue has soared by 133% since the previous quarter
Moderna's operating margin has surged by 64% YoY and by 48% QoQ
The net margin has surged by 62% year-on-year and by 47% since the previous quarter

Growth

What is Moderna's growth rate over time

Valuation

What is Moderna stock price valuation
P/E
N/A
P/B
18.54
P/S
207.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
202.69
The company's EPS rose by 27% YoY but it fell by 16% QoQ
MRNA's P/B is 144% above its last 4 quarters average of 7.6
The equity has soared by 120% YoY but it is down by 6% QoQ
MRNA's revenue has soared by 133% since the previous quarter
The stock's P/S is 27% above its last 4 quarters average of 163.2

Efficiency

How efficient is Moderna business performance
The company's return on sales has surged by 62% YoY and by 47% QoQ
Moderna's ROA has increased by 33% YoY and by 9% from the previous quarter
MRNA's return on equity is up by 27% year-on-year
The ROIC has grown by 13% YoY but it has contracted by 12% from the previous quarter

Dividends

What is MRNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MRNA.

Financial health

How did Moderna financials performed over time
Moderna's total assets is 146% more than its total liabilities
Moderna's total assets has soared by 192% YoY and by 33% from the previous quarter
The quick ratio has plunged by 86% from the previous quarter and by 67% YoY
The debt is 92% smaller than the equity
The company's debt to equity has surged by 167% YoY and by 33% QoQ
The equity has soared by 120% YoY but it is down by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.